Insulin Types and Dosing Strategies

Insulin Types and Dosing Strategies — scientific infographic poster
🩸 Interactive Visualization Blood Sugar & Insulin — eat a meal and watch glucose move Watch insulin escort glucose into cells and the liver bank glycogen, then switch on insulin resistance and see the curve change. Launch →

Table of Contents

  1. Why There Are So Many Insulins
  2. Rapid-Acting Bolus Insulins
  3. Ultra-Rapid and Inhaled
  4. Short-Acting (Regular) Insulin
  5. Intermediate — NPH
  6. Long-Acting Basal Insulins
  7. Premixed Insulins
  8. Pump-Compatible Insulins
  9. The Basal-Bolus MDI Regimen
  10. Pump Therapy and AID Systems
  11. Carb Counting Basics
  12. I:C Ratio, Correction Factor, and the 500/1800 Rules
  13. Basal Dosing and Basal Testing
  14. Dawn Phenomenon vs Somogyi
  15. Sick-Day Rules
  16. Exercise Adjustments
  17. Hypoglycemia Prevention in Brittle T1D
  18. Insurance and Cost Realities
  19. Key Research Papers
  20. Connections
  21. Featured Videos

Why There Are So Many Insulins

A healthy pancreas releases insulin in two patterns. There is a slow background drip that runs twenty-four hours a day to keep the liver from dumping too much glucose into the blood, and there are fast bursts at every meal that shove dietary carbohydrate into muscle and fat cells. Insulin by injection is an attempt to recreate both of those patterns with products that come out of a vial. No single insulin can do both jobs well — fast and short for meals, slow and flat for background — so pharmaceutical companies have engineered a menu of molecules, each tuned to a different onset and duration. This article describes every major category, how the types differ, and the dosing methods that diabetes educators and published trials describe.

For people new to insulin, the sheer number of names is intimidating. But the logic is simple: everything falls into one of five buckets — ultra-rapid, rapid, short, intermediate, long — plus premixed combinations. Once the onset, peak, and duration of each bucket are clear, the product names matter much less.

Rapid-Acting Bolus Insulins

Rapid-acting analogs are the workhorses of mealtime dosing. They appeared in the 1990s and replaced Regular insulin for most people because they match the speed of a carbohydrate meal far better. Three molecules share nearly identical pharmacology:

All three have an onset of roughly 15 minutes, a peak between 1 and 2 hours, and a total duration of 3 to 4 hours. In practice that means an injection 10 to 15 minutes before eating (not at the first bite) and the dose is mostly gone by the next meal. The tail is short enough that stacking — giving a second dose before the first is finished — is less dangerous than with Regular insulin, but it is still the most common cause of unexpected lows.

For most people there is no clinically important difference between insulin lispro, insulin aspart, and insulin glulisine. Choice is usually driven by insurance formulary, pump compatibility, or personal response; people who get site irritation or unpredictable absorption with one product often switch to another.

Ultra-Rapid and Inhaled

Two newer analogs squeeze the onset even shorter. Faster-acting insulin aspart adds niacinamide to aspart, which speeds absorption. Ultra-rapid insulin lispro adds treprostinil and citrate, which dilate the capillary bed around the injection and pull the drug into circulation faster. Both have onsets around 3 to 5 minutes, with a peak roughly 30 minutes earlier than the older analogs.

The practical advantage is postprandial control — the 1- and 2-hour glucose after a meal. For people whose continuous glucose monitor (CGM) traces show a big spike between eating and the two-hour mark even with pre-bolusing, a switch to one of these faster formulations often flattens that curve. They also shine for people who cannot reliably pre-bolus (toddlers, people with gastroparesis, people who have to eat unpredictably at work).

Inhaled insulin is human insulin as a dry powder. A single-use cartridge goes into a small inhaler and the dose is breathed in at the start of a meal. The U.S. label (DailyMed, revised May 2026) gives these timings from a study in 30 people with type 1 diabetes: a first measurable effect at about 12 minutes; a peak effect at about 35, 45, and 55 minutes after doses of 4, 12, and 48 units; and a return to baseline at about 90, 180, and 270 minutes — so the effect lasts longer as the dose rises. Insulin in the blood peaks 10 to 20 minutes after inhalation. It is used by people who dislike needles or want very tight postprandial numbers. Cartridges hold 4, 8, or 12 units, and larger doses are made by combining cartridges. The current label covers adults and children 6 years of age and older.

The label carries a boxed warning: sudden tightening of the airways (acute bronchospasm) has been seen in people with asthma and chronic obstructive pulmonary disease (COPD) who used inhaled insulin, and it is contraindicated in chronic lung disease such as asthma or COPD. A breathing test (spirometry, measuring FEV1) is required before starting, then after the first 6 months and every year after that. The label states that inhaled insulin is not recommended for people who smoke or who have recently stopped smoking, and not recommended for treating diabetic ketoacidosis.

In a 24-week trial in type 1 diabetes (Bode 2015; 174 people on inhaled insulin and 171 on injected insulin aspart, both with basal insulin), HbA1c fell by 0.21 percentage points with inhaled insulin and 0.40 with insulin aspart — within the trial's non-inferiority margin — though more people on insulin aspart reached an HbA1c under 7% (30.7% against 18.3%). The inhaled-insulin group had fewer low-glucose events (9.8 against 14.0 per patient-month) and a small weight loss (0.4 kg) instead of a gain (0.9 kg). Cough, generally mild, affected 31.6% of inhaled-insulin users against 2.3%, and led 5.7% to stop.

Short-Acting (Regular) Insulin

Regular insulin — also called R or human regular insulin — is plain recombinant human insulin. It has an onset of 30 minutes, peak at 2 to 4 hours, and duration of 6 to 8 hours. For decades it was the only mealtime option. Today it is mostly used for three reasons: cost, high-protein meals, and severe insulin resistance.

For cost: a large U.S. retail chain sells store-brand human regular insulin for about $25 a vial without a prescription in most states. Compared with $300 for a brand-name analog, that is life-saving for people without insurance, even though it is harder to use.

For high-protein meals: Regular's longer tail actually helps cover the delayed glucose rise from pizza, cheeseburgers, or a big steak dinner — the so-called "pizza effect," where dietary protein and fat slow carbohydrate absorption for hours. Some pump users run a "combo" or "dual-wave" bolus of rapid insulin, but a small dose of Regular in addition to rapid can do the same thing with a pen.

For severe insulin resistance: U-500 Regular insulin is five times more concentrated than standard U-100. It is reserved for people requiring more than about 200 units per day of total insulin, where U-100 volumes become impractical (imagine injecting 2 mL five times a day). U-500 dosing is a specialist-only territory because the timing and stacking behavior change — it behaves more like an intermediate than a true short-acting insulin.

Intermediate — NPH

NPH (Neutral Protamine Hagedorn) is Regular insulin mixed with a fish-sperm-derived protein that slows its release. Onset is 1 to 2 hours, peak 4 to 10 hours, duration 10 to 18 hours. It is cloudy — the vial or pen is rolled between the palms to resuspend the crystals before a dose is drawn.

NPH is the cheapest basal option — about $25 a vial as a retail store brand — and still the global workhorse outside wealthy countries. The downside is the peak. A 10-hour peak means that NPH taken at bedtime carries a real risk of 3 a.m. hypoglycemia, and NPH taken at breakfast can bring a late-afternoon low. Variability vial-to-vial and day-to-day is worse than with the true long-acting analogs.

For most insured patients, NPH has been replaced by glargine or degludec. For uninsured patients who cannot afford analogs, NPH plus Regular is a completely legitimate regimen — it is the regimen that kept people alive from the 1950s until the 1990s. It simply requires more discipline, more snacks, and more glucose monitoring.

Long-Acting Basal Insulins

Modern basal insulins are engineered to release at a slow, flat rate for roughly a full day or longer. Four products matter:

Whether the choice of basal insulin matters depends on the person. For someone whose numbers are stable on insulin glargine U-100, the product makes little difference. For someone waking up low at 3 a.m. despite careful dosing, a switch to glargine U-300 or degludec often fixes it. For someone who works rotating shifts or travels across time zones, degludec's flatness is a real quality-of-life gain.

Once-weekly basal insulins. Two once-a-week basal insulins, insulin icodec and insulin efsitora alfa, have been tested in large trials (the ONWARDS and QWINT programmes). The European Medicines Agency authorised icodec on 17 May 2024 for adults with type 1 or type 2 diabetes. In the United States, the Food and Drug Administration approved icodec on 26 March 2026 for adults with type 2 diabetes and extended that approval on 23 October 2026 to children 10 years and older with type 2 diabetes; it approved efsitora alfa on 23 September 2026 for adults with type 2 diabetes, and the efsitora label states that it is not recommended in type 1 diabetes. The approvals and the trial numbers are set out on Once-Weekly Basal Insulins. A 2024 review's meta-analysis of the phase 3 icodec trials (4,347 adults with type 1 or type 2 diabetes) found icodec lowered HbA1c slightly more than once-daily basal insulin (by 0.14 percentage points), with a weight gain of 0.62 kg and a similar overall frequency of low-glucose events; it worked best when used as basal insulin alone rather than with mealtime insulin. A 2025 review reports that in type 2 diabetes both weekly insulins matched once-daily basal insulin, and in some trials did better, with similar rates of clinically significant and severe lows, while in type 1 diabetes (the ONWARDS 6 and QWINT-5 trials) HbA1c fell about as much as with daily insulin degludec but lows were more frequent. A pooled safety analysis of ONWARDS 1–6 (2,170 people on icodec and 2,170 on daily basal insulin) found similar rates of all, serious, and severe adverse events; injection-site reactions, mostly mild, ran at 5.86 against 3.66 per 100 patient-years. Long-term heart outcomes and long-term safety are still open questions, the 2025 review notes. The first efsitora trial in people with type 2 diabetes new to insulin (QWINT-1) was published in 2025 and reviewed in a 2026 Drug and Therapeutics Bulletin commentary.

Premixed Insulins

Premixed insulins combine a basal and a bolus in one pen. Common ratios:

Premixed regimens are usually twice daily, before breakfast and before dinner. They are simpler than basal-bolus — two injections instead of five — and they suit people with steady schedules and steady meal sizes: older adults, people with cognitive impairment, people whose caregivers do the dosing. The trade-off is flexibility. The basal part cannot be adjusted separately during illness, nor the bolus part when a meal is skipped. For type 1 diabetes, premixed is generally not adequate. For stable type 2, it can be an excellent pragmatic choice.

Pump-Compatible Insulins

Insulin pumps deliver continuous subcutaneous infusion through a small cannula changed every 2 to 3 days. Only rapid-acting analogs are used in pumps: insulin lispro and insulin aspart, including their faster formulations. Insulin glulisine is U.S. Food and Drug Administration-approved for pump use but tends to crystallize in tubing over 48 hours and is less popular. Regular insulin is not used in modern pumps because its long tail destroys the math of automated dosing.

Some pump users prefer the faster formulations for the quicker meal response; others find the ultra-rapid formulations more likely to cause infusion-set irritation and stay with standard insulin lispro or insulin aspart. This is an individual trial.

The Basal-Bolus MDI Regimen

MDI means multiple daily injections. It is the gold-standard regimen for type 1 diabetes when not using a pump, and an excellent regimen for insulin-requiring type 2. The structure is:

Four to five injections a day sounds like a lot, but the pen needle is 4 mm long and thinner than a human hair. Most patients describe the injections as painless within two weeks. Basal-bolus dosing allows tight glucose control, at the cost of a learning curve.

Pump Therapy and AID Systems

An insulin pump replaces the basal insulin (with a programmable micro-drip of rapid insulin delivered every few minutes) and replaces mealtime pens (the wearer pushes buttons instead). Since a 2016 safety study of a hybrid closed-loop system (Bergenstal 2016, below), pumps have evolved into automated insulin delivery (AID) systems — also called hybrid closed-loop systems — that read the wearer's CGM in real time and adjust the basal rate minute-by-minute.

The commercial systems in the U.S. fall into a few designs:

In the six-month iDCL trial (Brown 2019; 168 people with type 1 diabetes aged 14 to 71), time in range (70–180 mg/dL) rose from 61% to 71% with a closed-loop system and stayed at 59% in the comparison group, which used a pump with a CGM (a sensor-augmented pump) rather than injections — an 11-percentage-point difference. Time below 70 mg/dL was 0.88 percentage points lower and HbA1c 0.33 points lower with the closed-loop system; no serious lows occurred in either group, and one episode of diabetic ketoacidosis occurred in the closed-loop group. AID systems are not magic — users still bolus for meals (except on the weight-based system), still change sites, still replace CGM sensors — but they dramatically reduce the mental load of T1D.

Carb Counting Basics

Carb counting means measuring the grams of carbohydrate in each meal so the bolus can be calculated. In practice three tools are used in combination:

Protein and fat matter too. A pure-carb meal (toast with jam) hits the bloodstream within 30 minutes. A high-fat, high-protein meal (pizza, lasagna, cheeseburger and fries) releases glucose over 4 to 6 hours — the pizza effect. Pump users handle this with extended or combo boluses. MDI users either split the bolus (half before the meal, half at the 90-minute mark) or add a small dose of Regular insulin. Most people with T1D eventually learn which foods do this to them. Dinner leftovers for lunch usually behave differently than the same food fresh — another quirk to log.

I:C Ratio, Correction Factor, and the 500/1800 Rules

Two numbers drive every bolus calculation:

Insulin-to-carb ratio (I:C) is how many grams of carbohydrate one unit of rapid insulin covers. An I:C of 1:10 means 1 unit per 10 grams of carb. A 60-gram meal = 6 units.

The classic starting estimate is the 500 rule: 500 divided by the total daily dose (TDD) of insulin. For someone taking 50 units a day in total, the I:C works out to about 500 ÷ 50 = 10, so 1 unit per 10 g carb. For Regular insulin instead of rapid, the 450 rule is used.

Correction factor (CF), also called insulin sensitivity factor (ISF), is how far one unit of rapid insulin lowers glucose. A CF of 50 means one unit lowers blood sugar by 50 mg/dL. A reading of 220 with a target of 120 means a 100-point drop needed = 2 units of correction.

Starting estimate: the 1800 rule (some endocrinologists use 1700). 1800 divided by the TDD. For a 50-unit-per-day person: 1800 ÷ 50 = 36 mg/dL per unit.

A pre-meal dose is the sum: carb dose + correction dose. For a 60 g carb meal with a pre-meal glucose of 220 and a target of 120, that comes to 6 + 2 = 8 units.

These are starting points. Real I:C and CF vary by time of day — most people are more insulin-resistant in the morning — by menstrual cycle, by exercise, by illness, and by stress. Pumps can be programmed with three or four different ratios across the day. MDI users can simply note that, say, breakfast needs 1:8 while dinner needs 1:12.

Basal Dosing and Basal Testing

Basal insulin is meant to cover glucose between meals without causing lows. The usual split is 40 to 50% of total daily dose as basal, with the rest as mealtime bolus. For a 50-unit-per-day person that means roughly 20 to 25 units of long-acting.

To confirm the basal dose is right, endocrinologists use basal testing. In the usual method a meal (say, lunch) is skipped with no bolus, and glucose is checked every 2 to 3 hours for the next 6 hours. If glucose stays flat within about 30 mg/dL of the starting value, the basal in that window is considered correct; a drift up means basal is too low, a drift down that it is too high. The test is repeated across breakfast, lunch, and dinner windows on different days to map the whole 24-hour profile. CGM users can do this passively by scanning the CGM line during accidental skipped meals.

The usual teaching is to change basal by no more than 10% every 3 days. Basal insulins take 3 to 5 days to reach a new steady state, so faster adjustments chase ghosts.

Dawn Phenomenon vs Somogyi

Many people with diabetes wake up with higher glucose than they went to bed with. The two classic explanations:

Somogyi is much rarer than it used to be thought — modern CGM data suggest dawn phenomenon accounts for the vast majority of morning highs. But the distinction matters because the two conditions need opposite adjustments. CGM answers the question in one night.

Sick-Day Rules

Infections, fevers, vomiting, and surgery all push glucose up and, in type 1 diabetes, can push ketones up fast. Sick-day plans taught by diabetes educators commonly cover these points:

Exercise Adjustments

Exercise is one of the most powerful glucose-lowering tools available, and also one of the most common causes of hypoglycemia. Three patterns matter:

Many people carry fast carbs (glucose tablets or candy, or a juice box) to every workout, and CGM users often set a low-alert threshold around 90 mg/dL during exercise to get a warning before symptoms.

Hypoglycemia Prevention in Brittle T1D

Some people, especially long-duration T1D patients, develop hypoglycemia unawareness — they no longer feel the shakiness, sweating, or hunger that warn of a low. Numbers can drop into the 40s before they notice. The standard toolkit:

Insurance and Cost Realities

U.S. insulin pricing has been a national political issue for a decade. The picture in 2026:

For people facing an unaffordable insulin bill, the insulin makers run manufacturer patient-assistance programmes; most provide free insulin to uninsured patients below about 400% of the federal poverty line. Rationing insulin carries a real risk of death.

Key Research Papers

Foundational peer-reviewed work on insulin analog pharmacology, basal-bolus and pump regimens, and the move toward automated insulin delivery. Each citation links to the paper via DOI or PubMed.

  1. Hirsch IB. Insulin Analogues. New England Journal of Medicine. 2005;352(2):174–183. — doi:10.1056/NEJMra040832
  2. Russell-Jones D, Bode BW, De Block C, et al. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes (onset 1). Diabetes Care. 2017;40(7):943–950. — doi:10.2337/dc16-1771
  3. Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients with Type 1 Diabetes. JAMA. 2016;316(13):1407–1408. — doi:10.1001/jama.2016.11708
  4. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes (iDCL). New England Journal of Medicine. 2019;381(18):1707–1717. — doi:10.1056/NEJMoa1907863
  5. Pickup JC, Sutton AJ. Severe Hypoglycaemia and Glycaemic Control in Type 1 Diabetes: Meta-Analysis of Multiple Daily Insulin Injections Compared with Continuous Subcutaneous Insulin Infusion. Diabetic Medicine. 2008;25(7):765–774. — doi:10.1111/j.1464-5491.2008.02486.x
  6. Holman RR, Farmer AJ, Davies MJ, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes (4-T). New England Journal of Medicine. 2009;361(18):1736–1747. — doi:10.1056/NEJMoa0905479
  7. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus (DCCT). New England Journal of Medicine. 1993;329(14):977–986. — doi:10.1056/NEJM199309303291401
  8. UK Prospective Diabetes Study (UKPDS) Group. Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. — doi:10.1016/S0140-6736(98)07019-6
  9. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S183–S215. — PubMed PMID: 41358900
  10. Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial. Diabetes Care. 2015;38(12):2266–2273. — PubMed PMID: 26180109
  11. Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA. 2017;318(1):33–44. — PubMed PMID: 28672316
  12. Lisco G, De Tullio A, De Geronimo V, et al. Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program). Biomedicines. 2024;12(8):1852. — PubMed PMID: 39200316
  13. Denimal D. Emerging perspectives on once-weekly insulins in type 1 and type 2 diabetes: a mini-review. Frontiers in Endocrinology. 2025;16:1656884. — PubMed PMID: 40937414
  14. Bajaj HS, Andersen SB, Hristova B, et al. Once-Weekly Insulin Icodec: Safety Profile in Type 2 and Type 1 Diabetes Based on a Pooled Analysis of ONWARDS 1-6. Endocrine Practice. 2026;32(10):1475–1482. — PubMed PMID: 42119975
  15. Khong TK, Vanniasegaram D. Once-weekly insulin (insulin efsitora) for patients with type 2 diabetes. Drug and Therapeutics Bulletin. 2026;64(7):100–102. — PubMed PMID: 42270287
  16. Brennan T. Does Insulin Price Reduction Suggest a Path Forward for Lowering Drug Costs? JAMA. 2023;329(16):1345–1346. — PubMed PMID: 36988976
  17. Myerson R, Kim NH, Romley J, et al. Insulin Costs and Use by Medicare Beneficiaries After the Inflation Reduction Act Out-of-Pocket Cap. JAMA. 2026;336(1):25–34. — PubMed PMID: 42250272

PubMed Topic Searches

Each link opens a live PubMed query so results stay current as new papers are indexed.

  1. PubMed: Insulin analog pharmacokinetics
  2. PubMed: Basal-bolus therapy in type 1 diabetes
  3. PubMed: Insulin degludec and nocturnal hypoglycemia
  4. PubMed: Automated insulin delivery and hybrid closed-loop systems
  5. PubMed: Insulin-to-carbohydrate ratio methodology
  6. PubMed: Dawn phenomenon in diabetes
  7. PubMed: Hypoglycemia unawareness in type 1 diabetes
  8. PubMed: Inhaled insulin clinical outcomes
  9. PubMed: Insulin biosimilars and interchangeability

Back to Table of Contents

Connections

Back to Table of Contents